Immunic (IMUX) stock rose 6% pre-market after regaining Nasdaq compliance on March 26. The firm closed above $1 for 20 straight days, removing delisting worries. This positive news follows the appointment of Mineralys CEO Jon Congleton to the company's board, bolstering leadership as it meets listing standards.